[go: up one dir, main page]

WO2008047394A1 - Compositions pour l'hygiène des paupières et l'hygiène périoculaire à tolérabilité oculaire et cutanée améliorée - Google Patents

Compositions pour l'hygiène des paupières et l'hygiène périoculaire à tolérabilité oculaire et cutanée améliorée Download PDF

Info

Publication number
WO2008047394A1
WO2008047394A1 PCT/IT2007/000663 IT2007000663W WO2008047394A1 WO 2008047394 A1 WO2008047394 A1 WO 2008047394A1 IT 2007000663 W IT2007000663 W IT 2007000663W WO 2008047394 A1 WO2008047394 A1 WO 2008047394A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation according
preparation
bisabolol
agents
hygiene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2007/000663
Other languages
English (en)
Inventor
Giulia Falcone
Enrico Boldrini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opocrin SpA
Original Assignee
Opocrin SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opocrin SpA filed Critical Opocrin SpA
Publication of WO2008047394A1 publication Critical patent/WO2008047394A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention concerns compositions for eyelid and pe- riocular hygiene with enhanced ocular and skin tolerability. More specifically, the invention concerns compositions indicated for deterging the ocular region and usable in general for the everyday hygiene of eyelids and eyelashes, but particularly suitable - owing to their capacity to limit irritation and burning sensations - for the treatment of inflammatory and infec- tive pathologies such as blepharitis and blepharoconjunctivitis, specially in the form of pads or wipes pre-moistened with the composition.
  • blepharitis is a widespread inflammatory pathology that involves redness, swelling, the formation of scabs, or even scales or ulcers, on eyelid margins, and may arise either alone or in combination with the inflammation of other surrounding regions such as the skin, conjunctiva and cornea.
  • Anterior blepharitis which mainly affects the front external part of the eyelids, normally arises with more marked symptoms in the morning, such as a burning sensation and localised itching accompanied by slight photophobia, and may be of bacterial, seborrheic or, less frequently, of mixed origin.
  • Bacterial blepharitis is mostly caused by staphylococci which concentrate at the base of the eyelashes to cause the infection of the mucosa and of the surrounding skin, and leads to hyper- aemia with blood vessel dilatation (rosettes) and the appearance of hard and friable scales around the eyelashes. If removed, the scales could also reveal small bleeding ulcers beneath. Hypersensitivity to staphylococcus toxins can lead to papillary conjunctivitis, corneal epiteliopathy and marginal keratitis. Blepharitis of seborrheic origin is instead probably caused by a dysfunction of the secretion of the eyelids glands with an overproduction of fatty acids which causes the formation of greasy scaling. The lid margin appears greasy and the eyelashes greasy and matted.
  • the scales are soft and evenly distributed, and do not leave ulcerations when removed.
  • Posterior blepharitis affects the internal part of the eyelid and is caused by dysfunctions of the glands situated immediately behind the eyelashes - Meibomian glands - which normally secrete lipid materials necessary for the maintenance of the tear film on the surface of the cornea, as well as for the lubrication of the eyelids themselves.
  • a typical sign is the presence of foaming in the lachrymal fluid, due to excess lipids, which have also undergone saponification processes. This secretion may also involve the onset of irritation and slight blurry vision, and small oily globules can come out of the gland orifices. In some cases the secretion stasis may favour the onset of chalazion.
  • Secondary effects are papillary conjunctivitis, keratopathy and lachrymal stability disorders.
  • blepharitis may also be caused by environmental factors such as dusts or smoke, or by allergic or endocrine factors, or may be secondary to avitaminosis or food poisoning. In all cases, the pathology may be difficult to cure and is recurrent, also tending to become chronic.
  • the therapy for blepharitis includes the use of compositions based on antibiotics and corticosteroids in the form of eye drops and ophthalmic ointments, which can be used particularly in the acute phase. In any case, proper eyelid hygiene is recommended, both during the therapy itself and for a long time afterwards in order to avoid any recurrence of the disorder.
  • the prescribed treatment is exclusively or mainly based on hot compresses and on the careful hygiene of the lid margin.
  • the importance of delicate but regular cleansing is because any stagnation of secretions, scales and bacteria on the eyelids and in the periocular region leads to further irritation and creates a vicious circle favouring a chronici- sation of the pathology. While the drainage of the gland ducts is further hindered, the pathogenic bacteria find the substrate ideal for their proliferation. Proper hygiene is thus fundamental also because, since it does not have any side effects as may be the case with a pharmacological type approach, it may be conducted over long periods thereby consolidating the results achieved.
  • a delicate detergent is often recommended, such as a neutral or baby shampoo, which must be diluted with water by the patient, however.
  • a neutral or baby shampoo In view of the frequency of application, at least once a day, and the considerable length of the treatment, the laboriousness of this operation inevitably creates problems of compliance.
  • hair shampoo products however delicate they may be, can still have an irritant effect when used in the vicinity of the eye, also due to components such as dyes or perfumes, which are not justifiable in a detergent for periocular hygiene to be used by subjects already suffering from an ophthalmic pathology underway.
  • US patent no. 5000868 proposes the use of a specially designed detergent for periocular hygiene that is essentially made up of an anionic surfactant with marked detergent and foaming properties, in combination with one or more non-ionic surfactants that reduce the irritant effect of the anionic surfactants, and with a further agent, defined as an induced non-ionic surfactant.
  • the latter component has the task of contributing to increasing the foaming properties and of limiting the irritating characteristics of the ani- onic surfactant.
  • Suifosuccinates are proposed as the anionic surfactants, while the non-ionic surfactants are selected from among the ethoxylated mono- and diglycerides and alkanolamides, and the induced non-ionic surfactant is an amine oxide.
  • the formulation can contain other ingredients such as antimicrobial agents and disodium edetate as a preservative. According to the PCT patent application, published with No.
  • formulations of the aforesaid type are undoubtedly effective as regards detergent capacity, the ocular and skin tolerability, including the mucosa, and the delicateness with regard to the natural moisturising and lubrication of the skin - which are essential features of prod- ucts designed for periocular hygiene and treatment - are certainly susceptible to improvement.
  • some of the surfactants proposed in the past for use in eyelid hygiene preparations are rather aggressive and not really suitable for cleansing the eyelid margin, particularly when it is already irritated due to blepharitis or to some other ophthalmic pathology. This holds not only for products of an ionic nature, but also for ethoxylated non-ionic surfactants, which can excessively dehydrate and degrease the skin, at least as regards the application considered here.
  • the surfactants present in preparations for eyelid hygiene are all intrinsically aggres- sive to a greater or lesser extent, particularly as regards the mucosa, and are thus not acceptable in ocular surface pathologies such as blepharitis and blepharoconjunctivitis with an inflammatory and/or infective component.
  • an object of the present invention is, therefore, to provide a preparation which, besides assuring a delicate and effective cleansing of the periocular region, thereby enabling the removal of debris and secretions that can build up around the eyelid margin, can also contribute to preventing the onset of irritation, which could be caused either by the presence of partly aggressive ingredients, such as detergents and preservatives, in the detergent formulation, or by the action of rubbing the affected area with the gauze or tissue employed for cleansing it. More- over, the preparation according to the present invention must contribute to limiting any development of the inflammatory process underway, and to reducing microbial growth in the affected ocular region.
  • ⁇ -bisabolol (R*,R*)- ⁇ ,4-dimethyl- ⁇ -(4-methyl-3-pentenyl)-3-cy- clohexene-1 -methanol] is a natural monocyclic sesquiterpene alcohol which can be isolated from the essential oils of various plants including, first of all, German camomile Matricaria chamomilla (or Matricaria recutita or Chamomilla recutita).
  • This plant is mainly grown in central and eastern Europe, Egypt and Argentina, and its flowers provide 0.5-1.5% of an essential oil containing the sesquiterpenes ⁇ -bisabolol (10-15%), bisabolol oxide A and B (10-25%) and chamazulene (0-15%), the latter being responsible for the bright blue or blue-green colour of the essential oil.
  • Both bisabolol and chamazulene contribute to the known anti-inflammatory properties of camomile essential oil.
  • the extracts or essential oils of matricaria have been used for centuries in the preparation of creams and ointments, used both in treating skin inflammations and as antibacterial agents, and also as anti-irritants in cosmetics.
  • the bisabolol component prevalently found in these natural extracts is the laevorotatory enantiomer ⁇ -(-)-bisabolol, even if another three stereoisomers have been isolated in much smaller quantities: ⁇ -(+)- bisabolol and the (-)-epi and (+)-epi forms.
  • the present invention specifically provides a cleansing emollient preparation for eyelid and periocular hygiene, consisting of an aqueous solution containing, as main ingredients, one or more surfactants, one or more antiseptic or bactericide agents and one or more emollient agents, and characterised by the fact that it comprises ⁇ -bisabolol as an anti-irritant agent.
  • the proposed preparation indicated for daily eyelid and periocular hygiene and also for the treatment of eyelid margin pa- thologies and/or conjunctivitis, contains ingredients that are useful for cleansing and disinfecting, contributes in the treatment of ocular symptoms of inflammation and is also devoid of any aggressive property with regard to both healthy or damaged skin tissues and mucosa.
  • the said ⁇ - bisabolol is preferably ⁇ -bisabolol racemate ( ⁇ -( ⁇ )-bisabolol), which turned out to be much more stable in an aqueous solution than the corresponding laevorotatory enantiomer of natural extraction, as the latter degrades quite quickly in the same conditions.
  • the said one or more surfactants are one or more non-ionic surfactants, and may, in general, include all those already known and used in the phar- pharmaceutical field, such as: the fatty acids esters of sucrose, the ethers of fatty alcohols and oligoglycosides (such as the alkyl polyglycosides known by the name "Triton ® "), the fatty acids esters of glycerine (such as glycerine mono/distearate or glycerol monolaurate), the fatty acids esters of sorbitan (such as "Span ® "), as well as the ethoxylated non-ionic surfactants, whose molecule contains polyoxyethylene chains (which are also known by other names, common or registered ones, including polyethylene glycol, polyethylene oxide, POE, PEG, PEO, Macrogol, Carbowax, Polyox or Polyoxyl).
  • Ethoxylated non-ionic surfactants which are the preferred category for the proposed preparation, specifically include the polyoxyethy- lated esters of fatty acids and sorbitan (that is, polysorbates such as "Tween ® "), the esters of fatty acids with polyoxyethylene (such as the polyoxyethylene stearates), the ethers of fatty acids and polyoxyethylene (such as polyoxyethylate lauryl ether, polyoxyethylene tridecyl ether or "Trideceth ® "), the ethers of alkyl phenols and polyoxyethylene (such as octylphenol polyoxyethylate), the block copolymers polyoxyethylene- polyoxypropylene (also known as poloxamers, such as "Pluronic ® "), and ethoxylated fats and oils (such as ethoxylated or polyethoxyated castor oil, also known as polyethylene glycol glycerol triricinoleate).
  • the said one or more ethoxylated non-ionic surfactants are selected from polyethoxyated or polysorbate fatty acids esters of sorbitan (Tween ® ), ethers of fatty alcohols and polyoxyethylene (Trideceth ® ) and their mixtures, and in particular consist of polyoxyethylene-10-tridecyl ether (Trideceth ® - 10) and polisorbate 20 or PEG(20)sorbitan-monolaurate (Tween ® -20).
  • the first one is used as an emulsifier, detergent and solubi- liser, and is approved by the FDA (Food and Drug Administration, USA) for topical use.
  • the second one is used as a detergent, solubiliser, emulsifier and dispersing agent and, like all polysorbates, is used also in the preparation of injectables, since it is non-pyrogenic, non-haemolytic and non- irritating.
  • the one or more antiseptic or bactericide agents are selected from among chlorhexidine or one of its salts or esters, benzalk- onium chloride and sodium merthiolate or thiomersal.
  • the first one of these is an antibacterial agent effective against a broad range of Gram- positive and Gram-negative organisms, particularly used in the form of an ester (acetate, digluconate) as a preservative for eyedrops and in the form of hydrochloride salt as a local antiseptic;
  • the second one is widely used in the ophthalmic field as a topical antiseptic and antimicrobial agent, while the third one is an organomercurial, anti-fungal and bacteriostatic antiseptic used both for topical use and as a pharmaceutical preservative.
  • the main antiseptic or bactericide agent included in the composition is preferably chlorhexidine digluconate (1 ,1'-hexamethylene bis[5-(4-chloro- phenyl)biguanide] di(D-digluconate), which has broad ranging bactericide and antiseptic properties and is widely used in dentistry, gynaecology and dermatology.
  • the proposed composition contains at least one moisturising, emollient and/or hydrating agent such as propylene glycol or glycerine and their derivatives, or the derivatives of cellulose such as hy- droxypropylcellulose.
  • Propylene glycol which is preferably included in the composition according to the present invention, has moisturising properties and facilitates water penetration in the tissues; moreover, by acting as a co-solvent, it helps to maintain the components in solution.
  • the preparation according to the present invention should preferably also include preserving agents and additional antimicrobial agents, particularly chosen from among benzalk- onium chloride, sodium merthiolate or thiomersal, methyl-, ethyl- and pro- pyl-paraben (methyl-, ethyl- and propyl-p-hydroxybenzoate), chlorobutha- nol, benzil alcohol, as well as chelant or sequestering agents such as ede- tates or EDTA.
  • the said preserving and antimicrobial agent is composed of methyl-p-hydroxybenzoate and propyl-p-hydroxybenzoate.
  • the proposed composition also preferably includes one or more tonicity adjusting agents which are often included in products for ophthalmic use in order to provide the solution with an osmolarity value near to the physiological one (around 300 m ⁇ sm/kg).
  • the composition can include one of the products conventionally used in the pharmaceutical art, such as sodium or potassium chloride, mannitol, dextrose, boric acid, or balanced saline solution.
  • the preferred isotonising agent in the composition according to the present invention is mannitol.
  • compositions for periocular hygiene may also include other natural extracts with a hydrating, skin protective, refreshing, tonic, moisturising, emollient and soothing action.
  • the detergent emollient composition contains the following components in an aqueous solution: polyoxyethylene-10-tridecyl ether, poly- sorbate 20, chlorhexidine digluconate, propylene glycol, ⁇ -bisabolol race- mate, methyl-paraben, propylparaben, mannitol, S ⁇ rensen phosphate buffer.
  • a particularly preferred formulation for the composition proposed is the one described below as Example 1.
  • the present invention also concerns a new emollient detergent wipe for eyelid and periocular hy- giene.
  • the wipe consists of a sterile substrate composed of absorbent material moistened with the aforesaid emollient detergent composition.
  • tow- elettes or wipes containing both disinfectant agents and detergents which are ideal for daily use, also in the presence of ophthalmic pathologies, because they are made of particular types of tissues that do not leave any residues, they contain useful ingredients for cleansing and disinfecting, they treat the periocular signs and symptoms of inflammation, they do not have any aggressive action for the eyes and are packaged in particular aluminium sealed sachets thereby avoiding contamination.
  • the sterile substrate of absorbent material is moistened with a total quantity of preaparation ranging between 1 ml and 3 ml, and preferably with a quantity of 2 ml.
  • Figure 1 shows a chromatogram of the preaparation according to the present invention, which highlights the peaks of the two preserving and antimicrobial agents contained therrein, methyl- and propyl-p-hydroxy benzoate.
  • the preferred formulation according to the present invention had the following composition:
  • the method for preparing the composition was as follows: the following components are placed inside a vessel in this order: Trideceth ® -10 (Sigma-Aldrich, Milan, Italy), Tween ® -20 (Sigma-Aldrich, Milan, Italy), bis- abolol racemate (BASF Italia Spa, Milan, Italy), propylene glycol (A.C.E.F. Spa, Piacenza, Italy) and the digluconate chlorhexidine solution (A.C.E.F. Spa, Piacenza, Italy). The mixture was stirred at room temperature for about 10 minutes.
  • the S ⁇ rensen phosphate buffer solution was prepared by dissolving 1.84 g of NaHbPO 4 H 2 O (monohydrated monobasic sodium phosphate) and 3.57 of Na 2 HPO 4 2HbO (dihydrated dibasic sodium phosphate) in 1 litre of deionised water.
  • the quantity of mannitol necessary to reach isotony was 13.52 g/l.
  • the preservatives methyl-p-hydroxy benzoate and propyl p- hydroxy benzoate were dissolved hot (80°C) in the previously prepared buffer solution.
  • the buffer solution containing the preservatives was finally added, after cooling, to the first prepared mixure.
  • the final formulation was then stirred, not vigorously, for about 30 minutes.
  • composition In order to assess the performance of the composition accordin ⁇ to the present invention in comparison with a preparation containing the same potentially aggressive ingredients but without bisabolol, a composition was prepared with the following components: Components % p/p Digluconate chlorhexidine, 20% solution 0.18
  • Example 2 The materials were the same as those of Example 1 and the preparation of the liquid solution was carried out according to the same procedure, but without using the ingredient ⁇ -bisabolol. Also the packaging in the form of wipes was carried out with the same procedure as described for the previous example. Characteristics and physico-chemical stability
  • the stability of the prepared composition was evaluated as re- gards its chemical-physical properties and with regard to any changes in the appearance of the solution.
  • the preparation was stored in closed glass vials at temperatures of 4, 25 and 37°C. TABLE 1
  • the quantitative determination of the preservatives present in the composition was carried out by means of high performance liquid chromatography (HPLC).
  • HPLC equipment consisted of a Shimadzu LC- 10ADvp system with UV SPD-10AVvp detector and CromatoPlus ® integration software.
  • the injection valve was a Rheodyne with 20 ⁇ l capacity.
  • the inverse phase column was a HyperClone C18 (5 ⁇ m, 250 x 4,60 mm, Phenomenex ® ).
  • the mobile phase consisted of 40% of an aqueous solution of KH 2 PO 4 (potassium phosphate dibasic anhydrous) 0.05M and 60% of acetonitrile; the flow was of 1 ml/min and the detection wavelength was 260 nm.
  • the quantitative determination was carried out via a comparison with an external standard curve.
  • the retention time was 5.5 minutes for methyl p-hvdroxv benzoate. and 5 minutes for ⁇ r ⁇ nvl h p >nrnnt ⁇ ->
  • the attached Figure 1 reports an example chromatogram.
  • the analytical method was as follows: a suitably measured quantity (100 ⁇ l) of the composition was diluted by adding 5 ml of acetonitrile. The suspension thus obtained first underwent vigorous stirring by means of a vortex and was then filtered (Minisart RC 25, 0,20 ⁇ m, Sartorius). The filtered solution was finally analysed in triplicate by HPLC with the aforesaid procedure. Table 2, below, reports the data on the stability of the preservatives after 90 days at a temperature of 4, 25 and 37 0 C.
  • New Zealand albino rabbits weighing 3.0-3.5 kg were used in the ocular irritation trials, which were carried out by instilling a drop of 50 ⁇ l in the lower conjuctival sack of only one eye, while the contralateral one was used as control. Administration was repeated every 5 minutes for a total duration of 30 minutes. A total of 20 rabbits were used.
  • the aim was to evaluate the soothing effect, as well as the emollient and deterging effect and tolerability (with particular regard to irritation and burning sensations) of the preparations described in the aforesaid Ex- amples 1 and 2. These two preparations differed, respectively, for the presence or absence of ⁇ -bisabolol.
  • Disposable wipes packaged in sachets, as described in Example 1 were moistened with 2 ml of both preparations, respectively.
  • the wipes moistened with the product of Example 1 i.e., the ones containing ⁇ -bisabolol
  • the wipes moistened with the product of Example 1 were effective not only in guaranteeing adequate hygiene of the eyelid margin, but also in appreciably limiting the bothersome irritation and burning sensation that can derive from cleansing and disinfecting components coming into contact with the damaged tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une préparation émolliente de nettoyage pour l'hygiène des paupières et l'hygiène périoculaire constituée d'une solution aqueuse comprenant comme ingrédients principaux un ou plusieurs tensioactifs, un ou plusieurs agents antiseptiques ou bactéricides et un ou plusieurs agents émollients, et comme agent anti-irritant un α-bisabolol. On utilise généralement la composition pour l'hygiène quotidienne des paupières et des cils, mais elle est plus particulièrement indiquée pour traiter des pathologies inflammatoires et infectieuses, telles que la blépharite et la blépharoconjonctivite, du fait de sa capacité à limiter les irritations et les sensations de brûlures. Ce produit peut être fourni, en particulier, sous forme de compresses de gaze stérilisée empaquetées ou sous forme de lingettes pré-humidifiées avec la préparation précitée.
PCT/IT2007/000663 2006-10-16 2007-09-25 Compositions pour l'hygiène des paupières et l'hygiène périoculaire à tolérabilité oculaire et cutanée améliorée Ceased WO2008047394A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2006A000557 2006-10-16
ITRM20060557 ITRM20060557A1 (it) 2006-10-16 2006-10-16 Preparato per l'igiene palpebrtale e perioculare ad elevata tollerabilita' oculare e cutanea

Publications (1)

Publication Number Publication Date
WO2008047394A1 true WO2008047394A1 (fr) 2008-04-24

Family

ID=39047509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000663 Ceased WO2008047394A1 (fr) 2006-10-16 2007-09-25 Compositions pour l'hygiène des paupières et l'hygiène périoculaire à tolérabilité oculaire et cutanée améliorée

Country Status (2)

Country Link
IT (1) ITRM20060557A1 (fr)
WO (1) WO2008047394A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173030A1 (fr) * 2016-03-31 2017-10-05 Pham Peter Angia Compositions contenant un mucilage végétal
WO2021234536A1 (fr) * 2020-05-18 2021-11-25 Offhealth S.P.A. Gel de contour des yeux et son procédé de préparation
US20220079848A1 (en) * 2020-09-17 2022-03-17 Tricia Morris 4-in-1 Facial and Body Wipe

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3543918A1 (de) * 1985-12-12 1987-06-19 Fresenius Ag Desinfizierende waschloesung fuer haut und haende
US5000868A (en) * 1987-04-03 1991-03-19 Wittpenn Jr John R Surfactant compositions
WO1993013750A1 (fr) * 1992-01-10 1993-07-22 Allergan, Inc. Compositions tensioactives non-ioniques, non-irritantes
US5527488A (en) * 1992-08-07 1996-06-18 Amway Corporation High viscosity anhydrous makeup remover gel
US6120782A (en) * 1995-06-13 2000-09-19 Mansouri; Zari Methods of delivering materials into the skin, and compositions used therein
WO2001008641A2 (fr) * 1999-08-02 2001-02-08 The Procter & Gamble Company Articles de soins personnels
WO2001047481A1 (fr) * 1999-12-28 2001-07-05 Pharmaskin Ltd. Composition de traitement des pellicules
WO2002026207A2 (fr) * 2000-09-28 2002-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata Formulation cosmetique
US20030114324A1 (en) * 2001-12-14 2003-06-19 Rainer Lange Cleansing compositions and their use in feminine hygiene wipes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3543918A1 (de) * 1985-12-12 1987-06-19 Fresenius Ag Desinfizierende waschloesung fuer haut und haende
US5000868A (en) * 1987-04-03 1991-03-19 Wittpenn Jr John R Surfactant compositions
WO1993013750A1 (fr) * 1992-01-10 1993-07-22 Allergan, Inc. Compositions tensioactives non-ioniques, non-irritantes
US5527488A (en) * 1992-08-07 1996-06-18 Amway Corporation High viscosity anhydrous makeup remover gel
US6120782A (en) * 1995-06-13 2000-09-19 Mansouri; Zari Methods of delivering materials into the skin, and compositions used therein
WO2001008641A2 (fr) * 1999-08-02 2001-02-08 The Procter & Gamble Company Articles de soins personnels
WO2001047481A1 (fr) * 1999-12-28 2001-07-05 Pharmaskin Ltd. Composition de traitement des pellicules
WO2002026207A2 (fr) * 2000-09-28 2002-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata Formulation cosmetique
US20030114324A1 (en) * 2001-12-14 2003-06-19 Rainer Lange Cleansing compositions and their use in feminine hygiene wipes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Kamillenöl -Vollbad", 14 June 2005 (2005-06-14), XP002470336, Retrieved from the Internet <URL:http://www.sanadoc.de/index.php?page=157&TypID=H&ItemID=3456> [retrieved on 20080219] *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173030A1 (fr) * 2016-03-31 2017-10-05 Pham Peter Angia Compositions contenant un mucilage végétal
US10117826B2 (en) 2016-03-31 2018-11-06 Peter Angia Pham Bodily lubricating and moisturizing compositions containing plant mucilage
WO2021234536A1 (fr) * 2020-05-18 2021-11-25 Offhealth S.P.A. Gel de contour des yeux et son procédé de préparation
US20220079848A1 (en) * 2020-09-17 2022-03-17 Tricia Morris 4-in-1 Facial and Body Wipe

Also Published As

Publication number Publication date
ITRM20060557A1 (it) 2008-04-17

Similar Documents

Publication Publication Date Title
DK2018103T3 (en) PRACTICES AND PREPARATIONS FOR THE TREATMENT OF INFECTIOUS OR INFECTIOUS colonization of the eyelid, eye surface, SKIN OR EAR
ES2666174T3 (es) Composiciones limpiadoras y métodos para utilizar las mismas
US20070231353A1 (en) Compositons and methods for maintaining eyelid hygiene
US11806415B2 (en) Hypochlorous acid-based eyelid cleansers
US8535736B2 (en) Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
WO2016022066A1 (fr) Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
WO2011085155A2 (fr) Formulations et procédés pour la dissolution de cérumen
WO2008047394A1 (fr) Compositions pour l&#39;hygiène des paupières et l&#39;hygiène périoculaire à tolérabilité oculaire et cutanée améliorée
KR20180125171A (ko) 눈꺼풀 위생을 유지하기 위한 조성물, 키트 및 방법
DK2604298T3 (en) Universal solutions for the care of contact lenses with chamomile
ITRM960207A1 (it) Detergente emolliente per l&#39;igiene palpebrale e perioculare.
US20250000762A1 (en) Hypochlorous acid-based eyelid cleansers
US20250064881A1 (en) Topical composition and applicator therefor for relieving chalazion
CA3231023A1 (fr) Onguents de traitement de la peau seche
GR1010664B (el) Υδατικο διαλυμα πολλαπλων χρησεων για φακους επαφης που περιεχει εκτοϊνη και μιγμα φυτικων παρασκευασματων
HK40048554A (en) Hypochlorous acid-based eyelid cleansers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827714

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827714

Country of ref document: EP

Kind code of ref document: A1